Aggrastat

Aggrastat is a brand name of tirofiban, approved by the FDA in the following formulation(s):

AGGRASTAT (tirofiban hydrochloride - injectable; injection)

• 
  Manufacturer: MEDICURE
  
  Approval date: April 20, 2000
  
  Strength(s): EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) ^[RLD]


• 
  Manufacturer: MEDICURE
  
  Approval date: May 17, 2002
  
  Strength(s): EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)
  

Has a generic version of Aggrastat been approved?

No. There is currently no therapeutically equivalent version of Aggrastat available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aggrastat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Novel sulfonamide fibrinogen receptor antagonists
  Patent 5,292,756
  Issued: March 8, 1994
  Inventor(s): Duggan; Mark E. & Egbertson; Melissa S. & Halczenko; Wasyl & Hartman; George D.
  Assignee(s): Merck & Co., Inc.
  A series of non-peptide derivatives of the formula ##STR1## that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
  
  Patent expiration dates:
  
  
  • May 14, 2012
    
    ✓ 
    Patent use: PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
  
  



• 
  Compositions for inhibiting platelet aggregation
  Patent 5,733,919
  Issued: March 31, 1998
  Inventor(s): Gelotte; Karl M.
  Assignee(s): Merck & Co., Inc.
  The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## as 2-S-(n-Butylsulfonylamino)-3-›4-(4-(piperidin-4-yl)butyloxy)phenyl!propion ic acid; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.
  
  Patent expiration dates:
  
  
  • October 23, 2016
    
  
  



• 
  Compositions for inhibiting platelet aggregation
  Patent 5,965,581
  Issued: October 12, 1999
  Inventor(s): Gelotte; Karl M.
  Assignee(s): Merck & Co., Inc.
  A composition is disclosed comprising about 0.25 mg/ml 2-S-(n-Butylsulfonylamino)-3 -›4-(4-(piperdin-4-yl)butyloxylphenyl!propionic acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein the composition osmolality concentration is between about 250-310 mOsmol/kg and the pH is in the range of between 5.5-6.5.
  
  Patent expiration dates:
  
  
  • October 23, 2016
    
  
  



• 
  Compositions for inhibiting platelet aggregation
  Patent 5,972,967
  Issued: October 26, 1999
  Inventor(s): Gelotte; Karl M.
  Assignee(s): Merck & Co., Inc.
  The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.
  
  Patent expiration dates:
  
  
  • October 23, 2016
    
  
  



• 
  Angioplasty procedure using nonionic contrast media
  Patent 5,978,698
  Issued: November 2, 1999
  Inventor(s): Sax; Frederic L.
  Assignee(s): Merck & Co., Inc.
  A method for treating patients in need of percutaneous transluminal coronary angioplasty which comprises administering nonionic contract media to the patient and treating the patient with a fibrinogen receptor antagonist.
  
  Patent expiration dates:
  
  
  • October 8, 2017
    
  
  



• 
  Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
  Patent 6,136,794
  Issued: October 24, 2000
  Inventor(s): Cook; Jacquelynn J. & Gould; Robert J. & Sax; Frederic L.
  Assignee(s): Merck & Co., Inc.
  A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.
  
  Patent expiration dates:
  
  
  • January 29, 2019
    
  
  

See also...

• Aggrastat Consumer Information (Wolters Kluwer)
• Aggrastat Consumer Information (Cerner Multum)
• Aggrastat AHFS DI Monographs (ASHP)
• Tirofiban Consumer Information (Wolters Kluwer)
• Tirofiban Consumer Information (Cerner Multum)
• Tirofiban AHFS DI Monographs (ASHP)